UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 32

Sortiert nach

Cediranib for Metastatic Alveolar Soft Part Sarcoma

Journal of clinical oncology, 2013-06, Vol.31 (18), p.2296-2302

2013

Link zum Volltext

Verfügbarkeit prüfen

Prospective evaluation of kidney and liver disease in autosomal recessive polycystic kidney disease-congenital hepatic fibrosis

Molecular genetics and metabolism, 2020-09, Vol.131 (1-2), p.267-276

2020

Link zum Volltext

Verfügbarkeit prüfen

MRI Robot for Prostate Focal Laser Ablation: An Ex Vivo Study in Human Prostate

Journal of imaging, 2018-12, Vol.4 (12), p.140

2018

Link zum Volltext

Verfügbarkeit prüfen

Template for MR Visualization and Needle Targeting

Annals of biomedical engineering, 2019-02, Vol.47 (2), p.524-536

2019

Link zum Volltext

Verfügbarkeit prüfen

ACR Appropriateness Criteria® Staging and Surveillance of Testicular Cancer: 2021 Update

Journal of the American College of Radiology, 2022-05, Vol.19 (5), p.S194-S207

2022

Link zum Volltext

Verfügbarkeit prüfen

ACR Appropriateness Criteria® Post-Treatment Surveillance of Bladder Cancer: 2021 Update

Journal of the American College of Radiology, 2021-05, Vol.18 (5S), p.S126-S138

2021

Link zum Volltext

Verfügbarkeit prüfen

ACR Appropriateness Criteria® Recurrent Lower Urinary Tract Infections in Females

Journal of the American College of Radiology, 2020-11, Vol.17 (11S), p.S487-S496

2020

Link zum Volltext

Verfügbarkeit prüfen

Phase II clinical trial of cediranib in patients with metastatic castration‐resistant prostate cancer

BJU international, 2013-06, Vol.111 (8), p.1269-1280

2013

Link zum Volltext

Verfügbarkeit prüfen

ACR Appropriateness Criteria® Acute Onset of Scrotal Pain-Without Trauma, Without Antecedent Mass

Journal of the American College of Radiology, 2019-05, Vol.16 (5), p.S38-S43

2019

Link zum Volltext

Verfügbarkeit prüfen

ACR Appropriateness Criteria® Post-Treatment Surveillance of Bladder Cancer

Journal of the American College of Radiology, 2019-11, Vol.16 (11), p.S417-S427

2019

Link zum Volltext

Verfügbarkeit prüfen

ACR Appropriateness Criteria® Lower Urinary Tract Symptoms-Suspicion of Benign Prostatic Hyperplasia

Journal of the American College of Radiology, 2019-11, Vol.16 (11), p.S378-S383

2019

Link zum Volltext

Verfügbarkeit prüfen

ACR Appropriateness Criteria® Penetrating Trauma–Lower Abdomen and Pelvis

Journal of the American College of Radiology, 2019-11, Vol.16 (11), p.S392-S398

2019

Link zum Volltext

Verfügbarkeit prüfen

Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas

European journal of cancer (1990), 2011-05, Vol.47 (7), p.997-1005

2011

Link zum Volltext

Verfügbarkeit prüfen

The gist in prostate volumetric imaging

Journal of vision (Charlottesville, Va.), 2019-09, Vol.19 (10), p.310

2019

Link zum Volltext

Verfügbarkeit prüfen

Searching for the gist of the prostate

Journal of vision (Charlottesville, Va.), 2019-09, Vol.19 (10), p.226

2019

Link zum Volltext

Verfügbarkeit prüfen

Representing 3D shapes based on implicit surface functions learned from RBF neural networks

Journal of visual communication and image representation, 2016-10, Vol.40, p.852-860

2016

Link zum Volltext

Verfügbarkeit prüfen

Missing the mark? Prostate cancer upgrading by systematic biopsy over fusion biopsy

Journal of clinical oncology, 2016-01, Vol.34 (2_suppl), p.62-62

2016

Link zum Volltext

Verfügbarkeit prüfen

A phase I/II study of TRC105 in combination with sorafenib in hepatocellular carcinoma (HCC)

Journal of clinical oncology, 2015-01, Vol.33 (3_suppl), p.291-291

2015

Link zum Volltext

Verfügbarkeit prüfen

Multi-institutional evaluation of multiparametric MRI and fusion-guided prostate biopsy in a biopsy-naive population

Journal of clinical oncology, 2016-01, Vol.34 (2_suppl), p.60-60

2016

Link zum Volltext

Verfügbarkeit prüfen

An analysis of sodium 18 f-fluoride PET/CT and prostate specific antigen (PSA) changes in men with metastatic castration resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2016-01, Vol.34 (2_suppl), p.203-203

2016

Link zum Volltext

Verfügbarkeit prüfen

A phase II study of TR105 in patients with hepatocellular carcinoma (HCC) who have progressed on sorafenib

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.e15177-e15177

2013

Link zum Volltext

Verfügbarkeit prüfen

TRC105 for the treatment of hepatocellular carcinoma: Preclinical data and preliminary results from two clinical trials evaluating monotherapy and combination with sorafenib

Journal of clinical oncology, 2014-01, Vol.32 (3_suppl), p.211-211

2014

Link zum Volltext

Verfügbarkeit prüfen

Biomarker correlates from the randomized phase 2 trial of the PARP inhibitor olaparib (O) with or without the antiangiogenic TKI cediranib (C) in recurrent platinum-sensitive ovarian cancer (NCT01116648)

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.5535-5535

2014

Link zum Volltext

Verfügbarkeit prüfen

Dosimetry and first human experience with 89Zr-panitumumab

American journal of nuclear medicine and molecular imaging, 2017-09, Vol.7 (4), p.195-203

2017

Link zum Volltext

Verfügbarkeit prüfen

Dosimetry and first human experience with 89 Zr-panitumumab

American journal of nuclear medicine and molecular imaging, 2017, Vol.7 (4), p.195

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 32

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(30)
Mit Volltextzugriff
(30)

Publikationsform

Artikel
(32)

Sprache

Englisch
(32)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Science & Technology
(13)
Life Sciences & Biomedicine
(10)
Appropriate Use Criteria
(7)
Appropriateness Criteria
(7)
Auc
(7)
Humans
(6)
Magnetic Resonance Imaging
(6)
Male
(6)
Middle Aged
(4)
Biological And Medical Sciences
(3)
Female
(3)
Magnetic Resonance Imaging - Methods
(3)
Medical Sciences
(3)
Oncology
(3)
Prostate Cancer
(3)
Prostatic Neoplasms - Pathology
(3)
Radiology, Nuclear Medicine & Medical Imaging
(3)
Technology
(3)
Tumors
(3)
Adult
(2)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Cediranib for Metastatic Alveolar Soft Part Sarcoma

Prospective evaluation of kidney and liver disease in autosomal recessive polycystic kidney disease-congenital hepatic fibrosis

MRI Robot for Prostate Focal Laser Ablation: An Ex Vivo Study in Human Prostate

Template for MR Visualization and Needle Targeting

ACR Appropriateness Criteria® Staging and Surveillance of Testicular Cancer: 2021 Update

ACR Appropriateness Criteria® Post-Treatment Surveillance of Bladder Cancer: 2021 Update

ACR Appropriateness Criteria® Recurrent Lower Urinary Tract Infections in Females

Phase II clinical trial of cediranib in patients with metastatic castration‐resistant prostate cancer

ACR Appropriateness Criteria® Acute Onset of Scrotal Pain-Without Trauma, Without Antecedent Mass

ACR Appropriateness Criteria® Post-Treatment Surveillance of Bladder Cancer

ACR Appropriateness Criteria® Lower Urinary Tract Symptoms-Suspicion of Benign Prostatic Hyperplasia

ACR Appropriateness Criteria® Penetrating Trauma–Lower Abdomen and Pelvis

Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas

The gist in prostate volumetric imaging

Searching for the gist of the prostate

Representing 3D shapes based on implicit surface functions learned from RBF neural networks

Missing the mark? Prostate cancer upgrading by systematic biopsy over fusion biopsy

A phase I/II study of TRC105 in combination with sorafenib in hepatocellular carcinoma (HCC)

Multi-institutional evaluation of multiparametric MRI and fusion-guided prostate biopsy in a biopsy-naive population

An analysis of sodium 18 f-fluoride PET/CT and prostate specific antigen (PSA) changes in men with metastatic castration resistant prostate cancer (mCRPC)

A phase II study of TR105 in patients with hepatocellular carcinoma (HCC) who have progressed on sorafenib

TRC105 for the treatment of hepatocellular carcinoma: Preclinical data and preliminary results from two clinical trials evaluating monotherapy and combination with sorafenib

Biomarker correlates from the randomized phase 2 trial of the PARP inhibitor olaparib (O) with or without the antiangiogenic TKI cediranib (C) in recurrent platinum-sensitive ovarian cancer (NCT01116648)

Dosimetry and first human experience with 89Zr-panitumumab

Dosimetry and first human experience with 89 Zr-panitumumab

Suchergebnisse filtern